First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers

• Main Authors: Macarena Hernández-Jiménez (Author), Samuel Martín-Vílchez (Author), Dolores Ochoa (Author), Gina Mejía-Abril (Author), Manuel Román (Author), Paola Camargo-Mamani (Author), Sergio Luquero-Bueno (Author), Bernd Jilma (Author), María A. Moro (Author), Gerónimo Fernández (Author), David Piñeiro (Author), Marc Ribó (Author), Víctor M. González (Author), Ignacio Lizasoain (Author), Francisco Abad-Santos (Author)
• Format: Book
• Published: Elsevier, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ApTOLL is an aptamer that antagonizes Toll-like receptor 4 and improves functional outcomes in models of ischemic stroke and myocardial infarction. The aim of this study was to characterize the safety and pharmacokinetics of ApTOLL in healthy volunteers. A first-in-human dose-ascending, randomized,...